Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » QuanDx to Distribute Zeesan's High-Risk HPV Genotyping Assay in Europe

QuanDx to Distribute Zeesan's High-Risk HPV Genotyping Assay in Europe

Nov 25, 2015
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – QuanDx, a San Francisco-based biotechnology firm focused on personalized cancer diagnostics, has announced a worldwide distribution agreement with Zeesan Biotech for that firm's MeltPro High Risk HPV Genotyping Assay. The deal excludes China, and terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

Avoiding the MARCH1 to 1-Mar Change

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

Overlooked Expertise

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In PCR

  1. Qiagen Q2 Revenues Soar 16 Percent on Coronavirus Testing Product Sales

  2. Facing 'Unfathomable' Demand, Quidel Ramps Up SARS-CoV-2 Test Production

    Premium

  3. SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency

    Premium

  4. Cleveland Clinic, Three Other Labs Get FDA EUAs for Coronavirus Tests

  5. Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.